Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer

University of Colorado Denver (CU Denver)

Status and phase

Terminated

Phase 2

Conditions

Prostate Cancer

Treatments

Drug: Dutasteride

Other: Placebo

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00985738

09-0247.cc

Details and patient eligibility

About

The purpose of this study is to determine the effect of short-term intake of daily Dutasteride in patients with prostate cancer.

Full description

This is a study of men who have undergone a standard 10 or more core biopsy for detection of prostate cancer and determined to have prostate cancer by having a Gleason score ≤ 7 (low to moderate risk 2-7). Of these men, one arm of a two arm randomized group will be administered a treatment regime of Dutasteride versus the control group who receive standard of care, prior to mapping biopsy. This proposal aims at studying the apparent effect of the use of Dutasteride (3 months) on initial tumor volume (at diagnosis) in men with low volume cancer before undergoing 3D mapping biopsy.

Enrollment

16 patients

Sex

Male

Ages

40 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

40-85 year old males
Patient is newly diagnosed with clinical Stage T1a-T2c prostate cancer based on transrectal guided extended prostate biopsy of at least 10 cores.
Patient elects to undergo 3D mapping biopsy at our center as part of prostate cancer management.
Patient will read, understand and sign the informed consent agreement
Patients must have a life expectancy of at least one year.
Gleason score ≤ 7 (low to moderate risk 2-7) 7= 3+4
Percentage positive core rate < 50% based on sextant or extended biopsy technique.
Prostate Volume (PV) >15 grams.
Negative imaging studies ( if available) during the staging period such as Bone scan, MRI and CT scan if PSA> 10 ng.dl before initiation of the study drug

Exclusion criteria

Any 5α-reductase inhibitors medications within the past 12 months before enrollment.
Known hypersensitivity to dutasteride, or other 5α-reductase inhibitors.
Anticipated blood donation within the next 90 days.
Serum PSA levels of >20ng/dl.
Clinical evidence of metastatic prostate cancer.
Two documented urinary tract infections in the past year
CHF, MI (within 6 months) or other symptomatic CVS disease
Other serious diseases (hematological, hepatic, renal, respiratory or psychiatric)
Enrollment in other studies for any disease in the past 30 days
Significant urinary incontinence
Diagnosis of cancer that in not considered cured, except BCC of skin
Prior transurethral resection of the prostate with a large tissue defect.
History of abdominoperineal resection for rectal cancer, rectal stenosis, or other major rectal pathology
Previous or concurrent radiotherapy, hormonal therapy or chemotherapy